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Caveolin-1 (CAV1) is an oncogenic membrane protein associated with endocytosis, extracellular matrix organisation,
cholesterol distribution, cell migration and signaling. Recent studies reveal that CAV1 is involved in metabolic
alterations – a critical strategy adopted by cancer cells to their survival advantage. Consequently, research findings
suggest that CAV1, which is altered in several cancer types, influences tumour development or progression by
controlling metabolism. Understanding the molecular interplay between CAV1 and metabolism could help uncover
druggable metabolic targets or pathways of clinical relevance in cancer therapy. Here we review from a cancer
perspective, the findings that CAV1 modulates cell metabolism with a focus on glycolysis, mitochondrial
bioenergetics, glutaminolysis, fatty acid metabolism, and autophagy.
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Cancer cells have anomalous metabolic features, which
enable them to adapt to constraints in the microenviron-
ment [1, 2]. Otto Warburg proposed that cancer cells have
impaired mitochondrial function and as such rely on high
turnover of a rather inefficient aerobic glycolysis instead of
oxidative phosphorylation (OXPHOS) [3–5]. While
aerobic glycolysis (often called Warburg effect) largely
holds true in several tumours, it is now known that tumours
also retain normal mitochondrial function, using glutamino-
lysis to support proliferation via tricarboxylic acid (TCA)
cycle [5, 6]. New evidences further highlight the importance
of lipid metabolism, the serine pathway, autophagic alanine
secretion, and macropinocytosis-mediated use of extracellu-
lar proteins for sustaining cancer nutrition and growth activ-
ities [5, 7–11]. Metabolic alterations in tumours are
coordinated by several genes, prominent among which are
TP53, MYC oncogene and hypoxia inducible factor 1α
(HIF1A) [8, 9, 12–16]. In addition, metabolic enzymes such
as pyruvate kinase muscle isoform (PKM2), lactate dehydro-
genase A (LDHA), phosphofructose kinase A (PFKA)
isoform, isocitrate dehydrogenase (IDH) and phospho-
glycerate kinase (PGK1) confer oncogenic phenotypes* Correspondence: christoph.meyer@medma.uni-heidelberg.de
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“oncometabolites” (e.g. hydroxyglutarate, fumarate, lactate
and ketones) can promote tumourigenesis in diverse ways,
including by increasing cancer stemness, upregulating
oncogene expression and reactive oxygen species amplifi-
cation [18–22]. A detailed insight on molecular regulators
of metabolic alterations could enhance the prospects of
identifying cancer drug targets. In this article, we review
evidences that CAV1 – a protein known to regulate chol-
esterol distribution, signal transduction, cell migration,
and endocytic vesicular trafficking [23–25] – represents
one such regulator of cell metabolism, especially in cancer
cells.Relevance of Caveolin-1 in cancer
Caveolin-1 is a 22 kDa protein encoded by CAV1 gene,
and occupies flask-shaped plasma membrane invagina-
tions called caveolae. It is one of three known caveolins
(CAV1, 2 and 3) and is ubiquitously expressed in all cell
types as is CAV2; CAV3 is mostly found in skeletal mus-
cles [23, 25]. Besides earlier studies that implicated
CAV1 in endocytosis, signaling and lipid disorders, re-
search activities in the last two decades also focused on
clarifying its relevance in cancer [23–33]. Consequently,
CAV1 was found to be overexpressed in cancers of liver,
colon, breast, kidney, lung, among others [29], and acts as
a tumour promoter or suppressor depending on tumourle is distributed under the terms of the Creative Commons Attribution 4.0
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function, it has been reported that high expression of
CAV1 drives tumourigenesis by inhibiting apoptosis,
facilitating anchorage-independent growth, drug resist-
ance as well as metastasis [30, 33–39]. For instance, CAV1
expression in liver cancer patients was found to positively
correlate with differentiation status, increased portal vein
invasion, intrahepatic metastasis, and to predict overall
survival outcome [37]. Accordingly, in vitro mechanistic
study showed that CAV1 overexpression induced known
mediators of migration and invasion, namely matrix metal-
loproteinases 2 and 9, and vascular epidermal growth factor
[37]. Indeed, CAV1 and caveolae, which mediate molecular
trafficking and contain signaling molecules such as non-
receptor tyrosine kinases and endothelial nitric oxide
synthase (eNOS), have long been proposed as potential
therapeutic targets for disrupting tumour angiogenesis,
progression and metastasis [40].
On the other hand, CAV1 acts as a tumour suppressor in
some settings in that its low expression favours tumour
progression [41–43]. For instance, in NIH3T3 cells onco-
genically transformed by H-Ras induction, high CAV1 ex-
pression in the mitochondria reduced cell proliferation
[43]. Codeficiency of CAV1 and the tumour suppressor, ad-
enomatous polyposis coli, enhanced colorectal tumouri-
genesis in mice [44]. Furthermore, loss of stromal CAV1 in
human breast cancer is associated with increased tumour
recurrence, metastasis and poor clinical outcome [41].
Consistently, and contrary to its tumour promoting func-
tion highlighted above [37], high CAV1 expression im-
proved overall survival in liver cancer patients, ostensibly
by countering eNOS activity [42]. Altogether, accumulating
evidences consistently support that CAV1 plays an import-
ant role in cancer progression – the specific nature of
which seems to depend on several factors, including cancer
type and stage, lesions on CAV1 or its associated genes, its
protein expression level and subcellular localisation. The
fact that CAV1 could serve as a clinical biomarker [45, 46]
further emphasizes its importance in cancer. However, des-
pite knowledge of its expression pattern and roles in differ-
ent cancers, it is still unclear whether CAV1 expression is a
property that accompanies or directly drives altered metab-
olism, or if changes in energy balance modulate CAV1 level
towards or against cancer progression.
CAV1 in glycolysis
The preference of cancer cells for aerobic glycolysis is an
evasive pro-survival strategy. This makes glycolysis an at-
tractive therapeutic target in cancer, especially if its molecu-
lar regulators are identified and well characterized. Several
studies reveal that CAV1 is involved in the modulation of
glycolytic activities (Figs. 1 and 2). For instance, CAV1 ex-
pressing colon cancer cells undergo increased glycolysis
upon exposure to inhalation anaesthesia (isoflurane), andare thus protected from tumour necrosis factor associated
apoptosis [47]. High CAV1 expression in advanced colon
cancer increased glucose uptake and ATP production by
stimulating transcription of glucose transporter 3 (GLUT3,
encoded by SLC2A3) [48]. Further, knockdown of CAV1 re-
duced cellular glucose uptake and lactate output (indicative
of suppressed Warburg effect), reduced intracellular ATP,
and triggered autophagy through activation of AMPK-p53
signaling [48]. In prostate cancer, immunoprecipitation
and signaling studies showed that CAV1 interacts with in-
sulin- and IGF-1 receptors (IR/IGF-1R), and can stimulate
IR kinase activities by also interacting with low-density
lipoprotein receptor-related protein 6 (LRP6). Accordingly,
both LRP6 and CAV1 stimulate IR/IGF-1R signaling and,
through AKT signaling activation, enhance glucose uptake,
lactate output and cell proliferation – these effects corre-
lated positively with hexokinase 2 (HK2) and GLUT3
expression [49]. Noteworthy, however, the authors
reported that the expression of some glycolytic enzymes
like enolase 1 (ENO1), PKM2 and LDHA were unchanged
upon CAV1 knockdown.
Furthermore, CAV1 enhanced sensitivity to anti-
diabetic drug (metformin) in a study comparing two
non-small-cell lung cancer cell lines, Calu-1 and Calu-6,
which express high and low CAV1 levels, respectively
[50]. Specifically, metformin reduced phosphorylation of
IGF-1 receptor substrates [AKT and Forkhead transcrip-
tion factor 3a (FOXO3A)], suppressed IGF1-dependent
cell proliferation, and increased AMPK phosphorylation
as well as AMP/ATP ratio in Calu-1. In line, ectopic
overexpression of CAV1 in Calu-6 enhanced sensitivity
to metformin, as observed by increased AMP/ATP ratio
and AMPK phosphorylation [50]. This CAV1-mediated
metformin sensitivity may extend beyond glycolysis since
the drug also acts on complex I of the electron transport
chain in cancer cells; hence it offers further clue for in-
vestigating CAV1 expression and response to anti-
metabolic drugs.
CAV1 provides a docking site for glycolytic enzymes. For
instance, in caveolae of vascular smooth muscle cells
and lymphocytes, the rate-limiting glycolytic enzyme phos-
phofructose kinase (PFK) as well as aldolase co-localised
with CAV1 by binding to its scaffolding domain [51]. Like-
wise, the intracellular metabolite profile of endothelial cells
revealed a decrease in glycolytic intermediates (e.g. 3-
phosphoglycerate, fructose-6-phosphate and glucose-6-
phosphate) upon CAV1 knockdown, indicating perturbed
glycolysis, even though the effect on glucose consumption
was not reported [52]. Thus, it highlights an interesting pos-
sibility that CAV1 could influence the localisation of rele-
vant glycolytic mediators in cancer as depicted in Fig. 3b.
There are contexts in which CAV1 level is inversely
related to glycolytic phenotypes. This has been reported in
its crosstalk with HIFs, which are crucial transcriptional
Fig. 1 CAV1 influences metabolic processes in normal and cancer cells
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transporters, and also mediators of angiogenesis and
tumour metastasis [53]. For instance, CAV1 is a direct tar-
get of HIF1 and HIF2, and is upregulated under hypoxia
in clear cell renal cell carcinoma [54]. However, overex-
pression of activated HIF1α reduced CAV1 level, caused
upregulation of glycolytic enzymes towards enhanced
aerobic glycolysis, and increased lactate output in immor-
talized fibroblasts (hTERT-BJ1 cells). The fibroblasts ex-
pressing activated HIF1α also promoted xenograft tumour
growth upon co-injection with breast cancer cells (MDA-
MB-231) in nude mice [55]. This implies that downregula-
tion of CAV1 in the stromal fibroblast compartment – in
parallel with increased aerobic glycolysis – is a mechanism
by which HIF1α promotes cancer progression. Further-
more, upregulation of several glycolytic enzymes, includ-
ing aldolase A, enolase 1, PGK1, PKM2 and LDHA was
observed in bone marrow derived stromal cells from Cav1
knockout (KO) mice [41]. In invasive ductal carcinoma,
CAV1 is reduced at the early stage of progression and pre-
dicts poor survival outcome. Mechanistically, reducedCAV1 expression enabled the induction of transcription
factor NRF2 (NF-E2-related factor 2), which activates
anti-oxidant manganese superoxide dismutase (MnSOD)
that triggers AMPK-dependent glycolysis [56]. As a proof,
ectopic expression of CAV1 in invasive ductal carcinoma
cells (MCF7) suppressed NRF2 expression, the induction of
MnSOD, and decreased aerobic glycolytic phenotype as
measured by extracellular acidification and lactate output
[56]. Further evidences have suggested that low CAV1 ex-
pression correlate with high reliance on glucose metabol-
ism. For example, CAV1 deficiency increased carbohydrate
metabolism in mice as determined by high respiratory ex-
change ratio, and prevented a metabolic switch to free fatty
acids including during fasting. Specifically, hepatic gluco-
neogenesis emerged as a possible pathway to sustain glu-
cose supply in Cav1-KO mice as revealed by upregulation
of glucose-6-phosphatase (G6PC3) and LDHD [57]. More-
over, in a study on three different CAV1-deficient mouse
strains, loss of CAV1 delayed liver regeneration and de-
creased survival after partial hepatectomy [58]. In the strain
where regeneration still occurred, the loss of CAV1 was
Fig. 2 Schematic representation of metabolic processes and targets associated with CAV1 based on research findings
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drate metabolism, as blocking glycolysis with glucose
analogue (2-deoxy-glucose) further reduced survival and
suppressed liver regeneration [58]. In a cancer context, low
CAV1 and high glycolytic phenotypes would suggest a
tumour suppressor function, but contradicts its role
as a tumour promoter as discussed earlier. Taken to-
gether, the underlying mechanisms for the apparently
context-dependent links between CAV1 and glycolysis
remain largely unclear. More studies are required to
elucidate the influence of CAV1 on glucose utilisation and
glycolytic enzymes, especially in CAV1 overexpressing tu-
mours, and to determine whether glycolysis modulates the
expression and function of CAV1 in normal and cancer
cells.
CAV1 in mitochondrial bioenergetics
Beyond aerobic glycolysis, cancer cells still retain intact
mitochondrial functions and can use alternative metabo-
lites to support energy production. CAV1 has been associ-
ated with mitochondrial number and bioenergetic function
in various cell types. For instance, mitochondria of hepatic
cells in hypercholesterolemic rabbits were found to have
high localisation of CAV1 [59]. Intravenous injection of
mice with antennapedia-CAV1 (AP-CAV1) peptide–toincrease CAV1 translocation across cell membrane–led to
a darker electron-dense mitochondrial matrix, lower super-
oxide dismutase and catalase activity as compared to
controls, suggesting that CAV1 is required for maintaining
mitochondrial architecture and function. AP-CAV1
treatment also restored respiratory chain subunit proteins
(complexes I–V), preserved mitochondrial function and
suppressed apoptotic cell death [59]. Consistently, increased
CAV1 expression was observed in an in vitro model of
active microglia along with increased mitochondrial
number, respiration, and glycolysis [60]. Colon cancer cells
(HCT116) that overexpress CAV1 also had its abundant
localisation in the mitochondria and, in the low expressing
cells (HT29), overexpression of CAV1 led to its enrichment
in the mitochondria and reduced apoptosis [61]. These
findings provide clues that CAV1 could enhance mito-
chondrial functions to support tumour progression, details
of which are yet to be fully understood. On the other hand,
high CAV1 in the mitochondria suppresses proliferation
in H-Ras driven tumour cell model [43]. Specifically,
neoplastic transformation triggered by oncogenic
H-Ras12v in NIH3T3 cells suppresses basal intracellular
calcium (Ca2+) level, Ca2+ influx and also CAV1 expres-
sion. Further, reintroduction of CAV1 enhanced Ca2+ up-
take into mitochondria, suppressed cell growth, colony
ab
Fig. 3 CAV1 and a hypothetical model of its role in cancer cell metabolism. a. A simplified diagram of CAV1. b. Model depicting CAV1 and its
potential influence on metabolism in cancer cells expressing it in high or low levels
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CAV1 level may suppress mitochondrial function as a
mechanism to mediate a suppressor activity in H-Ras-
driven tumours [43].
CAV1 may modulate mitochondrial function by regu-
lating cholesterol flux. In line with this notion, loss ofCAV1 in mouse embryonic fibroblasts (MEFs) led to chol-
esterol accumulation in mitochondrial membrane, and in-
creased reactive oxygen species (ROS) and cell death upon
OXPHOS activation [62]. Increased circulating ROS was
also observed in Cav1-KO mice, in which gonadal white
adipose tissue presented with mitochondrial dysfunction.
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membrane potential as further validated in vitro with
CAV1-deficient MEFs [57]. However, the authors sug-
gested that impaired mitochondrial function is a tissue-
specific consequence of CAV1 loss, as comparison of oxy-
gen consumption rates in liver and lung tissues revealed di-
vergent results [57]. In cultured bovine aortic endothelial
cells, knockdown of CAV1 caused an increase in mito-
chondrial ROS production, intracellular H2O2, and reduced
the intracellular redox balance indicator [the ratio of re-
duced to oxidized glutathione (GSH/GSSG)] [52]. In the
same study, Cav1-KO mice had increased oxidative stress
as determined by high level of 8-isoprostane (a biomarker
of lipid peroxidation and oxidative stress). Noteworthy, al-
though membrane potential was increased, suppressed
CAV1 expression did not significantly alter mitochondria
abundance [52]. Altogether, these observations strongly
link CAV1 expression to mitochondrial function, and could
be relevant in understanding how CAV1 affects mitochon-
drial bioenergetics in cancer.
Glutaminolysis – CAV1 in the alternative tumour
energy pathway?
Glutaminolysis is a metabolic process in which glutam-
ine is converted to α-ketoglutarate for onward utilisation
in TCA cycle. Through this process, glutamine serves as
alternative energy-rich substrate for cancer cells to meet
the excessive nutritional demands that result from rapid
proliferation [6, 63]. Currently, there is a limited insight
on the association between CAV1 and glutaminolysis
(Figs. 1 and 2). However, it has been proposed that glu-
tamine availability inversely correlates with CAV1 expres-
sion in tumour stromal compartment, and that fibroblasts
lacking CAV1 secrete more glutamine [64]. Accordingly,
cancer associated fibroblasts cultured in high glutamine
media had suppressed CAV1 expression and increased au-
tophagy [64]. It is unclear how the observed loss of CAV1
and high glutamine availability work to drive tumour pro-
gression; however, the authors suggested that autophagy
in the fibroblasts may serve as a key source of energy-rich
glutamine to fuel mitochondrial activity in adjacent cancer
cells [64]. This proposition aligns with inverse association
of CAV1 with autophagy induction as reported by some
studies (discussed later), but does not establish a direct
link between enhanced glutaminolysis and high CAV1 ex-
pression as also seen in cancer.
Enhanced glutaminolysis via glutaminase induction is a
known transcriptional function of MYC in cancer [14, 65].
Its encoded protein, c-MYC, regulates CAV1 and both
promote tumour progression in prostate and colon cancer
[49, 66–69]. Hence, although not yet proven, CAV1 could
play a role in c-MYC-driven glutamine metabolism in tu-
mours. It is also probable that CAV1 regulates the expres-
sion and localisation of amino acid transporters in plasmamembrane. Consistent with the latter, the glutamine up-
take activity of sodium neutral amino acid transporter 3
(SNAT3) was abolished following its coexpression with
dominant-negative CAV1 mutant in Xenopus laevis oo-
cytes [70]. The CAV1 mutant, when expressed 2 days after
expressing SNAT3, prevented the rapid suppression of glu-
tamine uptake by protein kinase C activator, phorbol-12-
myristate-13-acetate [70]. These findings raise the possibil-
ity that CAV1 controls glutamine uptake and utilisation in
cancer by influencing SNAT3 or other amino acid trans-
porters reviewed in [71, 72], and could lead to novel un-
derstanding of glutamine dependency in cancer cells.
CAV1 in fatty acid metabolism
Several studies have reported that CAV1 modulates fatty
acid metabolism in normal and cancer cells (Fig. 1).
Fatty acid synthase (FASN) is a crucial enzyme in fatty
acid biosynthesis, and catalyzes the formation of palmi-
tate from acetyl-CoA and malonyl-CoA. Aberrant FASN
function is associated with tumourigenesis in various hu-
man cancers, making it a potential cancer drug target
[73–75]. CAV1 and FASN are coordinately regulated in
melanoma and prostate cancers, implying that their
concomitant expression may enhance tumourigenesis
[76–78]. The mechanism explaining CAV1 and FASN
interaction to promote tumourigenesis is still unknown,
but a possible biochemical link is the dynamics in palmi-
toylation – a posttranslational modification process, in
which long chain fatty acids (mainly palmitate) bind to
cysteine residues in proteins via a thioesther bond. CAV1
has palmitoylated residues (Fig. 3a), and the effects of pal-
mitoylation on membrane proteins include regulation of
membrane interaction, stability, spatial organisation, and
intracellular trafficking reviewed in [79, 80], all of which
could alter how CAV1 interacts with metabolic targets. It
is likely that by being co-expressed with FASN, CAV1
ensures availability of the lipids required for maintaining
membrane integrity of tumour cells. Insights could be
gained from study in visceral adipose tissue (VAT) of
obese patients where a positive correlation between CAV1
expression and lipogenic genes, e.g. acetyl-CoA carboxyl-
ase and FASN was reported [81].
CAV1 modulates several lipid metabolic processes in
hepatocytes, including hepatic lipid storage, fatty acid oxi-
dation (FAO) and ketogenesis [57, 58, 82]. For instance,
Cav1 deletion led to reduced hepatic triglyceride content
and impaired lipid storage [58]. Furthermore, genomic
profiling of liver, adipose tissue, and MEFs from fasted
CAV1-deficient mice, all showed downregulation of lipid
metabolic processes as a major consequence of loss of
CAV1 [82]. These findings corroborate a previous report
on reduced whole body FAO in Cav1-KO mice [57]. The
reduction of FAO and ketogenesis in CAV1-deficient mice
is attributed to impaired hepatic peroxisome proliferator
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though some PPARα target genes (e.g. Gsta2, Scarb1,
Nox4 and Per2) were upregulated in the CAV1-deficient
mouse liver, there was a predominant suppression of sev-
eral others, including carnitine palmitoyltransferases
(Cpt1α and Cpt1β), acetyl-CoA acyltransferase 2 (Acaa2),
and dehydrogenase/reductase (SDR Family) – Dhrs4 and
Dhrs8. In line, over 15 genes involved in peroxisomal and
mitochondrial FAO, such as Acox1, Hadhb, Cpt2 and
Acadm, were downregulated upon loss of CAV1. Ketogen-
esis was likewise suppressed as confirmed by downregula-
tion of 3-hydroxybutyrate dehydrogenase and reduced
plasma level of β-hydroxybutyrate [82]. These findings
underscore a strong link between CAV1 and lipid metabol-
ism that is yet untested in cancer settings. Further evidence
reveals that loss of CAV1 causes a switch from lipid to-
wards glucose metabolism, as observed in endothelial cells
[52], and murine hepatocytes [58]. Accordingly, decreased
glycolytic intermediates after CAV1 knockdown in endo-
thelial cells was attributed to accelerated utilisation,
whereas increased level of fatty acids, such as palmitate,
arachidonate, myristate, and essential fatty acids (e.g. lino-
leic and linolenic acids) were linked to a defective lipid me-
tabolism [52]. Similarly, analysis of liver tissue showed that
CAV1-deficient mice resorted to carbohydrate – instead of
fatty acid metabolism [58]. Whether CAV1 influences such
a crucial switch in cancer is not yet reported. Indeed, it is
worthy to recall that lipids are important for raft remodeling
– a crucial function of CAV1 [23, 25, 26]. Therefore, beyond
modulating lipid metabolism, CAV1 depletion can com-
promise the functions of other molecules involved in lipid
raft function. An example of such molecule is fatty acid-
binding protein 7 (FABP7), which binds to and facilitates
uptake of long-chain fatty acids. Recently, it was found that
CAV1 mediates lipid raft activity of FABP7, namely receptor
accumulation [83]. Specifically, knockout of Fabp7 in mice
suppressed CAV1 and ligand-dependent accumulation of
Toll-like receptor 4 (TLR4) in astrocytes upon lipopolysac-
charide stimulation, whereas overexpression of CAV1 in
FABP7-deficient astrocytes was sufficient to restore TLR4
recruitment [83].
CAV1 level may determine the effect of lipid load on
cancer cells. For instance, docosahexaenoic acid (DHA)–
an omega-3 polyunsaturated fatty acid – is associated with
cancer risk, progression and therapy [84, 85]. CAV1 partic-
ipates in DHA mediated apoptosis in MDA-MB-231 cells
[86]. Accordingly, DHA treatment caused cholesterol-
dependent co-localisation of CAV1 and epidermal growth
factor receptor (EGFR) with lysosome associated mem-
brane protein 1 (LAMP-1), with an onward down-
regulation of lipid-raft associated onco-proteins, including
EGFR, HSP90, AKT and SRC [86]. Furthermore, expres-
sion of tyrosine-14 phosphorylated CAV1 accelerated
palmitate-induced apoptotic cell death in pancreatic betacells [87]. Taken together, these studies reveal that CAV1
is associated with fatty acid metabolism, offering insights
for onward investigation in cancer. It will also be interest-
ing to determine whether differential expression of CAV1
influences the expression or function of fatty acid enzymes
that have recently emerged to be important mediators in
cancer, e.g. acyl-CoA synthetase, carnitine palmitoyltrans-
ferase 1C, and carnitine acyltransferase [88–90].
Caveolin-1 in metabolic abnormalities – obesity
and insulin resistance
Obesity and insulin resistance, the major cause of type 2
diabetes (T2DM), are two intricately connected metabolic
abnormalities of significant global health burden, and are
strongly linked to cancer [91, 92]. For instance, in the case
of obesity, there has emerged sufficient evidence in
humans that reduced body fatness also reduces the risk of
most cancers, prominent among which are liver, pancre-
atic, ovarian cancers, and multiple myeloma [92]. Simi-
larly, a recent consensus report concluded that although
several questions remain unanswered, “diabetes (primarily
type 2) is associated with increased risk for some cancers
(liver, pancreas, endometrium, colon and rectum, breast,
bladder)” though also the reduced risk of prostate cancer
[93]. Thus, whether in obesity and insulin resistance, un-
derstanding the activity of CAV1 could shed light on its
role in metabolism that may be applicable in cancer. In-
deed, studies in cancer and normal cells show that CAV1
modulates insulin signaling [48, 49, 57]. The loss of CAV1
leads to insulin resistance, and several of its genetic vari-
ants are associated with type 2 diabetes and lipid disorders
[94]. It is believed that CAV1 stabilizes insulin receptor
and so enhances cellular response to insulin stimuli as is
necessary for promoting glucose uptake and metabolism.
Besides, in a differentiating murine preadipocyte model
3T3-L1, Cav1 promoter hypomethylation caused its over-
expression and phosphorylation of its protein, accompan-
ied by increased expression of insulin receptor, glucose
transporter 4, and adipokines (adiponectin, interleukin 6
and leptin) [95]. CAV1 expression, therefore, apparently
contribute to both insulin sensitivity and obesity. Consist-
ent with the latter, CAV1 is overexpressed in VAT and
subcutaneous adipose tissue of obese patients with
normoglycaemia or T2DM (basically characterized by
hyperglycemia and hyperinsulinemia) – and is positively
correlated with body fat and body mass index [96].
Although still poorly understood, the mechanistic link
between obesity, CAV1 and cancer may be partly due to
increased adipokine activity. For instance, murine high
fat diet model of obesity exposed to anti-obesity drug
(orlistat) or restricted caloric intake had smaller adipocyte
size, low CAV1 and suppressed adipokines (leptin and
resistin) – in vivo growth of murine (B16F10) and human
(A375) melanoma cell lines was also reduced in the obese
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tion with the adipokines enhanced proliferation and
CAV1 level in A375 cells in vitro [97]. This finding
supports a potential involvement of CAV1 via adipokines
in obesity-driven cancer. Indeed, the involvement of
CAV1 or its genetic variants in obesity and insulin resist-
ance offers a pathophysiological clue for future under-
standing of its role in tumour glucose and fatty acid
metabolism.
CAV1 in autophagy
Autophagy is a process in which cells breakdown their
cytoplasmic components to release metabolites for meet-
ing nutritional needs [98]. Thus, autophagy is either a rou-
tine metabolic process in itself or is a pivotal mechanism
initiated for long-term cellular energy homeostasis, espe-
cially during starvation [98, 99]. Autophagy is crucial in
cancer, which explains why its inhibition leads to cancer
cell death [100–102]. In addition, there is evidence that
autophagy in surrounding tumour cells, as recently shown
in pancreatic stellate cells [11], may actually be key for
tumour nutrient supply in the hypovascularized micro-
environment. Several studies have found autophagy to be
very context-dependent. Thus, while CAV1 is implicated
in the regulation of autophagy reviewed in [33, 103], it is
not surprising that the molecular mechanisms seem in-
consistent – supporting both direct and inverse associa-
tions. For example, in HCC, CAV1 inhibited autophagy
while promoting cell proliferation, migration, and angio-
genesis [104]. Accordingly, CAV1 inversely correlated with
autophagy markers ATG5 and BECLIN-1 in clinical HCC
and cell lines, while its knockdown increased autophago-
some formation [104]. A well-acknowledged marker of au-
tophagic activity commonly used to indicate increased
autophagosome formation or decreased turnover is the
microtubule-associated protein 1 light chain 3 beta (LC3B)
[105, 106]. The suppression of CAV1 markedly increased
LC3B-II in endothelial cells [52]. CAV1 deficiency in breast
cancer also promoted late stage autophagy by enhancing
lysosomal function and autophagosome-lysosome fusion
towards improved cell survival under nutrient starvation
[107]. Similarly, knockdown of CAV1 in stromal fibroblast
induced autophagy, and hypoxia-induced degradation of
CAV1 led to upregulation of autophagy markers [108].
Studies also show that CAV1 is directly associated
with or regulates autophagy. For example, CAV1 corre-
lates with estradiol-mediated autophagy in the BT474
breast cancer cell line. These cells expressed higher
CAV1 and autophagy-related proteins (BECLIN-1, light
chain (LC3)-II and ATG12/5) upon estradiol treatment
[109]. In lung epithelial cells, CAV1 interacts with and
regulates expression of autophagy proteins, notably
ATG12, ATG5, and the ATG12-ATG5 complex that is
important for autophagosome formation [110]. CAV1 isalso an upstream regulator of transient receptor potential
melastatin 3 (TRPM3), which controls Ca2+ and Zn2+ flux,
and induces oncogenic autophagy via LC3A/B-II [111]. In
this setting, TRPM3 expression requires CAV1, while
knockdown of their encoding genes reduce LC3A/B-II ac-
cumulation in renal carcinoma cell lines [112]. Cav1 was
also among genes downregulated following bleomycin-
induced pulmonary fibrosis in mice with autophagy gene
Atg4b deletion [112]. The downregulation of Cav1 coin-
cided with altered expression of several profibrotic genes,
including upregulation of Tgfbr2, Smad3, Tgfb1, Tgfb3,
and suppression of Smad4, 7 and Snai1 [112], suggesting
a link between its expression and fibrosis via autoph-
agy. In non-small lung adenocarcinoma cells (A549),
expression of CAV1 was protective by blocking a
switch from autophagy to apoptosis [113]. Taken to-
gether, these studies show a context-dependent in-
volvement of CAV1 in autophagy that requires further
clarification, especially in cancer types where CAV1 is
a key player.
Conclusions
There is abundant evidence that CAV1 plays diverse
roles in normal and cancer cell metabolism (Figs. 1 and
2), which appears to be spatiotemporal and dependent
on cell types, microenvironmental factors, nutritional
availability and probably even additional perturbations,
e.g. hypoxia or drug treatment. For instance, while CAV1
overexpression may drive glycolysis and glucose depend-
ency, its knockdown also enhances glycolytic phenotypes
in cancer and normal cells. Similar discrepancies also exist
in autophagy, where different studies show that both loss
and overexpression of CAV1 induces the lysosomal
marker LC3B. Given these conflicting findings, more stud-
ies are required to unravel the exact mechanisms by which
CAV1 controls cell metabolism – especially in cancer
types associated with its high expression. Based on evi-
dences from literature, we propose that mechanisms by
which CAV1 modulate cancer metabolism may include:
enabling the expression of membrane-localized metabolic
enzymes; coordinating a switch between metabolic path-
ways; relaying signals for transcriptional activation or sup-
pression of metabolic regulators, or inhibiting anti-
metabolic stimuli (Fig. 3b).
To understand the role of CAV1 in cancer metabolism,
studies should employ experimental models that are as
close to the human cancer situation as is possible. In
addition, studies designed to extend current knowledge on
CAV1 function should endeavor to validate some previous
observations using the same experimental models, i.e. cell
and tissue types (Table 1). This will ensure consistency
and also help to detect confounding experimental vari-
ables. Diseases such as obesity and diabetes could also
provide an avenue through which molecular clues on the
Table 1 Cell, tissue types and disease conditions in which CAV1 was found to correlate with or influence metabolic processes
CAV1 promoted or directly correlated
with metabolic processes
Ref. CAV1 suppressed or inversely correlated
with metabolic processes
Ref.
Glycolysis
•Colon cancer [HCT116, HT29, LoVo]*
•Prostate cancer [LNCaP, PC-3]
Smooth muscle cells, lymphocytes
47, 48
49
51
BAEC
CA fibroblast [hTERT–BJ1]
Breast cancer cell [MCF7]
Mouse liver (including gluconeogenesis)
52
55
56
58
Mitochondrial function
BAEC
Hepatic cells
Microglia
Colon cancer [HCT116, HT29]
MEFs
52
59
60
61
57, 62
NIH3T3 cells oncogenically transformed
with H-RAS mutant
43
Glutamine metabolism
Xenopus laevis oocyte 70 Stromal fibroblast; [hTERT–BJ1] 64, 103
Fatty acid metabolism
BAEC 52 – –
Mouse liver 57, 58, 82
Mouse hepatocyte [AML12] 58
Adipocytes 57, 82
MEFs 57, 82
Melanoma, prostate cancer 76, 77, 78
Metabolic diseases
Obesity: Diabetes:
Adipose tissues of patients 96 Insulin insensitivity, hyperglycemia 57
Murine preadipocyte model [3T3-L1] 95 Insulin resistance (Type 2 diabetes) 94
High fat diet mouse model 97
Autophagy
Breast cancer cell [BT474] treated with estradiol 109 BAEC 52
Lung epithelial cells [BEAS-2B] 110 •Hepatocellular carcinoma [HCCLM3]* 104
•Renal carcinoma cell [786-O, A498]* 111 •Breast cancer [MCF7, MDA-MB-231]* 107
Murine fibrotic lung tissue 112 MEFs 107
Lung cancer cell [A549] 113 CA fibroblast [hTERT–BJ1] 108
MEFs mouse embryonic fibroblasts, BAEC Bovine aortic endothelial cells, CA Cancer associated; •Including in clinical samples; In squared bracket [] are cell lines
used for mechanistic studies; *other cell lines are mentioned in the studies
Nwosu et al. Molecular Cancer  (2016) 15:71 Page 9 of 12involvement of CAV1 in cellular metabolism can be un-
raveled for subsequent investigation in cancer. From a
technical viewpoint, complementing CAV1 gain or loss of
function studies with high throughput molecular biology
methods, such as metabolomics, genomics and proteo-
mics, will help to clarify its function in cancer cell
metabolism.
Finally, the identification of key initiating factors –
whether genomic or signaling mutations – that drive
metabolic alterations are crucial steps in fine-tuning
anti-cancer strategies. For instance, if low CAV1 expres-
sion in cancer also causes high dependency on glucose
over lipid metabolism as reported in non-cancer cells
[52, 58], then it raises an attractive prospect of using
CAV1 expression levels to stratify cancer patients intothose that could benefit from either inhibitors of glucose
or lipid metabolism. Interestingly, we highlighted evi-
dences that CAV1 interacts with known mediators of al-
tered metabolism, e.g. LDHA, PKM2 and FASN, which
are currently being studied as cancer drug targets [17,
114, 115]. It is therefore conceivable that understanding
the expression and function of CAV1 in cancer could
serve as a pointer for exposing novel metabolic genes or
pathway alterations of clinical importance.
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